日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia

靶向 CCL2/CCR2 信号可克服急性髓系白血病中的 MEK 抑制剂耐药性

Rucha V Modak #, Katia G de Oliveira Rebola #, John McClatchy #, Mona Mohammadhosseini #, Alisa Damnernsawad, Stephen E Kurtz, Christopher A Eide, Guanming Wu, Ted Laderas, Tamilla Nechiporuk, Marina A Gritsenko, Joshua R Hansen, Chelsea Hutchinson, Sara J C Gosline, Paul Piehowski, Daniel Bottomly,

Upregulation of HOXA3 by isoform-specific Wilms tumour 1 drives chemotherapy resistance in acute myeloid leukaemia

亚型特异性 Wilms 肿瘤 1 介导的 HOXA3 上调驱动急性髓系白血病化疗耐药

Basil Allen ,Lindsey Savoy ,Peter Ryabinin ,Daniel Bottomly ,Reid Chen ,Bonnie Goff ,Anthony Wang ,Shannon K McWeeney ,Haijiao Zhang

Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy

维奈克拉联合治疗增强急性髓系白血病治疗的临床相关性

Christopher A Eide #, Stephen E Kurtz #, Andy Kaempf, Nicola Long, Sunil Kumar Joshi, Tamilla Nechiporuk, Ariane Huang, Charles A Dibb, Akosha Taylor, Daniel Bottomly, Shannon K McWeeney, Jessica Minnier, Curtis A Lachowiez, Jennifer N Saultz, Ronan T Swords, Anupriya Agarwal, Bill H Chang, Brian J

Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia

急性髓系白血病中FLT3和LSD1双重靶向破坏MYC超级增强子复合物

William M Yashar # ,Brittany M Curtiss #,Daniel J Coleman,Jake VanCampen,Garth Kong,Jommel Macaraeg,Joseph Estabrook,Emek Demir ,Nicola Long,Daniel Bottomly,Shannon K McWeeney,Jeffrey W Tyner ,Brian J Druker ,Julia E Maxson,Theodore P Braun

Integrative analysis of drug response and clinical outcome in acute myeloid leukemia

急性髓系白血病药物反应与临床结果的综合分析

Daniel Bottomly ,Nicola Long ,Anna Reister Schultz ,Stephen E Kurtz ,Cristina E Tognon ,Kara Johnson ,Melissa Abel ,Anupriya Agarwal ,Sammantha Avaylon ,Erik Benton ,Aurora Blucher ,Uma Borate ,Theodore P Braun ,Jordana Brown ,Jade Bryant ,Russell Burke ,Amy Carlos ,Bill H Chang ,Hyun Jun Cho ,Stephen Christy ,Cody Coblentz ,Aaron M Cohen ,Amanda d'Almeida ,Rachel Cook ,Alexey Danilov ,Kim-Hien T Dao ,Michie Degnin ,James Dibb ,Christopher A Eide ,Isabel English ,Stuart Hagler ,Heath Harrelson ,Rachel Henson ,Hibery Ho ,Sunil K Joshi ,Brian Junio ,Andy Kaempf ,Yoko Kosaka ,Ted Laderas ,Matt Lawhead ,Hyunjung Lee ,Jessica T Leonard ,Chenwei Lin ,Evan F Lind ,Selina Qiuying Liu ,Pierrette Lo ,Marc M Loriaux ,Samuel Luty ,Julia E Maxson ,Tara Macey ,Jacqueline Martinez ,Jessica Minnier ,Andrea Monteblanco ,Motomi Mori ,Quinlan Morrow ,Dylan Nelson ,Justin Ramsdill ,Angela Rofelty ,Alexandra Rogers ,Kyle A Romine ,Peter Ryabinin ,Jennifer N Saultz ,David A Sampson ,Samantha L Savage ,Robert Schuff ,Robert Searles ,Rebecca L Smith ,Stephen E Spurgeon ,Tyler Sweeney ,Ronan T Swords ,Aashis Thapa ,Karina Thiel-Klare ,Elie Traer ,Jake Wagner ,Beth Wilmot ,Joelle Wolf ,Guanming Wu ,Amy Yates ,Haijiao Zhang ,Christopher R Cogle ,Robert H Collins ,Michael W Deininger ,Christopher S Hourigan ,Craig T Jordan ,Tara L Lin ,Micaela E Martinez ,Rachel R Pallapati ,Daniel A Pollyea ,Anthony D Pomicter ,Justin M Watts ,Scott J Weir ,Brian J Druker ,Shannon K McWeeney ,Jeffrey W Tyner

Genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways mediating sorafenib resistance in acute myeloid leukemia

全基因组 CRISPR 筛选可识别出介导急性髓系白血病索拉非尼耐药性的 MAPK 和 MTOR 通路调节剂

Alisa Damnernsawad, Daniel Bottomly, Stephen E Kurtz, Christopher A Eide, Shannon K McWeeney, Jeffrey W Tyner, Tamilla Nechiporuk

Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia

Luxeptinib (CG-806) 靶向作用于急性髓系白血病的 FLT3 和激酶簇

William G Rice, Stephen B Howell, Hongying Zhang, Nasrin Rastgoo, Andrea Local, Stephen E Kurtz, Pierrette Lo, Daniel Bottomly, Beth Wilmot, Shannon K McWeeney, Brian J Druker, Jeffrey W Tyner

Functional proteomics of patient derived head and neck squamous cell carcinoma cells reveal novel applications of trametinib

患者来源的头颈部鳞状细胞癌细胞的功能蛋白质组学揭示了曲美替尼的新应用

Myles Vigoda, Chase Mathieson, Nathaniel Evans, Carolyn Hale, Jennifer Jennings, Olivia Lucero, Sophia Jeng, Daniel Bottomly, Daniel Clayburgh, Peter Andersen, Ryan Li, Daniel Petrisor, Jeffrey W Tyner, Shannon McWeeney, Molly Kulesz-Martin

The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance

急性髓系白血病(AML)微环境催化了吉瑞替尼耐药性的逐步演变。

Sunil K Joshi ,Tamilla Nechiporuk ,Daniel Bottomly ,Paul D Piehowski ,Julie A Reisz ,Janét Pittsenbarger ,Andy Kaempf ,Sara J C Gosline ,Yi-Ting Wang ,Joshua R Hansen ,Marina A Gritsenko ,Chelsea Hutchinson ,Karl K Weitz ,Jamie Moon ,Francesca Cendali ,Thomas L Fillmore ,Chia-Feng Tsai ,Athena A Schepmoes ,Tujin Shi ,Osama A Arshad ,Jason E McDermott ,Ozgun Babur ,Kevin Watanabe-Smith ,Emek Demir ,Angelo D'Alessandro ,Tao Liu ,Cristina E Tognon ,Jeffrey W Tyner ,Shannon K McWeeney ,Karin D Rodland ,Brian J Druker ,Elie Traer

Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations

慢病毒驱动的癌症药物耐药性突变发现

Paul Yenerall, Rahul K Kollipara, Kimberley Avila, Michael Peyton, Christopher A Eide, Daniel Bottomly, Shannon K McWeeney, Yan Liu, Kenneth D Westover, Brian J Druker, John D Minna, Ralf Kittler